Pleasant Exports Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Pleasant Exports Pharmaceutical Export Portfolio Dataset — 10 Products, $2.9M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Pleasant Exports — Pharmaceutical Exporter Profile (2026) | 10 Products, $2.9M Trade | TransData Nexus

Pleasant Exports

Indian Pharmaceutical Exporter · Oncology Specialist · $2.9M Total Trade · DGFT Verified

Pleasant Exports is an Indian pharmaceutical exporter with a total trade value of $2.9M across 10 products in 6 therapeutic categories. Based on 535 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Carboplatin ($1.1M), Semaglutide ($814.8K), Mesalamine ($265.6K).

Pleasant Exports — Export Portfolio & Destination Treemap

Pleasant Exports pharmaceutical export portfolio — 10 products across 6 therapeutic categories. Source: Indian Customs (DGFT).

Who is Pleasant Exports? — Company Overview & Market Position

Pleasant Exports is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 1994, the company is headquartered in Chennai, Tamil Nadu, India. Initially operating as a limited liability partnership (LLP), Pleasant Exports transitioned to a private limited company in July 2021, adopting the name Pleasant Exports India Private Limited. The company is registered under the Corporate Identification Number (CIN) U51909TN2021PTC144665. As of the latest available data, Pleasant Exports reports an authorized and paid-up capital of ₹5,000,000. The company is managed by three directors: Pranay Palepu, Prashanth Palepu, and Palepu Srinivasa Gopal. The registered office is located at Lalitha Sadan, Room No. 1, 3rd Floor, Old and New No. 1, Ramachandra Road, Mylapore, Chennai, Tamil Nadu, 600004, India.

What Does Pleasant Exports Export? — Product Portfolio Analysis

Top Products by Export Value

1Carboplatin$1.1M 2Semaglutide

Product Portfolio — Top 10 by Export Value

Pleasant Exports exports 10 pharmaceutical products across 6 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Carboplatin	Oncology	$1.1M	24	1.5%	11
2	Semaglutide	Advanced Diabetes Medications	$814.8K	98	16.4%	2
3	Mesalamine	Gastrointestinal	$265.6K	86	0.0%	13
4	Empagliflozin	Diabetes & Endocrine	$254.7K	128	3.8%	6
5	Fluticasone	Respiratory	$246.7K	136	0.1%	15
6	Cytarabine	Advanced Oncology	$131.9K	10	1.2%	11
7	Canagliflozin	Advanced Diabetes Medications	$56.0K	25	6.3%	5
8	Lomustine	Advanced Oncology	$10.5K	7	10.2%	2
9	Topotecan	Advanced Oncology	$8.2K	12	0.2%	7
10	Saxagliptin	Advanced Diabetes Medications	$4.0K	9	0.1%	6

Pleasant Exports exports 10 pharmaceutical products across 6 therapeutic categories with a total export value of $2.9M. The top category is Oncology (37.4% of portfolio), followed by Advanced Diabetes Medications (30.5%), indicating a concentrated portfolio with the top 5 products accounting for 92.6% of total export value.

Pleasant Exports — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Pleasant Exports operates manufacturing facilities in Chennai, Tamil Nadu, India. While specific details regarding plant capacities and specializations are not publicly disclosed, the company's focus on finished pharmaceutical formulations suggests that its facilities are equipped to handle the production of tablets, capsules, syrups, and injections. The strategic location in Chennai provides access to key ports, facilitating efficient export operations.

3Key Leadership

The leadership team at Pleasant Exports comprises three directors:

Pranay Palepu: Designated Partner, appointed on April 1, 2019.

Prashanth Palepu: Designated Partner, appointed on June 27, 2017.

Palepu Srinivasa Gopal: Designated Partner, appointed on June 27, 2017.

These individuals oversee the company's strategic direction and operations, leveraging their expertise to drive growth and maintain compliance with industry standards.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Pleasant Exports Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Pleasant Exports has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for its products in these regions, ensuring compliance with stringent quality and safety standards. Specific details regarding the number of approved Abbreviated New Drug Applications (ANDAs), Drug Master Files (DMFs), and inspection histories are not publicly available. However, the company's adherence to international regulatory requirements underscores its commitment to delivering high-quality pharmaceutical products globally.

2Emerging Markets

Pleasant Exports has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's products have been prequalified by the World Health Organization (WHO), facilitating access to these regions. This prequalification enables Pleasant Exports to supply essential medicines to countries with significant healthcare needs, contributing to global health initiatives.

3Geographic Strategy

The company's geographic strategy demonstrates a balanced approach, with a diversified portfolio across various therapeutic categories and a presence in multiple international markets. This diversification mitigates concentration risk and positions Pleasant Exports to capitalize on growth opportunities in both developed and emerging markets. The strategic direction focuses on expanding market access while maintaining compliance with international regulatory standards.

Pleasant Exports — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Pleasant Exports' FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly disclosed. However, the company's established presence in the U.S. market indicates adherence to FDA regulations and quality standards. The absence of publicly available inspection histories suggests a need for further transparency in regulatory compliance reporting.

2WHO & EU GMP

Pleasant Exports' products have been prequalified by the World Health Organization (WHO), indicating compliance with international quality standards. The company holds EU Good Manufacturing Practice (GMP) certificates, ensuring that its manufacturing processes meet the stringent requirements set by the European Medicines Agency (EMA). These certifications reflect the company's commitment to maintaining high-quality production standards.

3CDSCO & Indian Regulatory

In India, Pleasant Exports holds manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO), authorizing the production of pharmaceutical formulations. The company has obtained approvals from state drug controllers, facilitating the distribution of its products within India. Additionally, Pleasant Exports has secured export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), enabling the export of its products to various international markets.

Pleasant Exports — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the pharmaceutical export sector, Pleasant Exports faces competition from both domestic and international companies. Key competitors include established Indian pharmaceutical exporters and multinational corporations with a presence in the same therapeutic categories. While specific market share comparisons are not publicly available, Pleasant Exports' focus on high-demand products such as Semaglutide and Carboplatin positions it competitively in the market.

2Key Differentiators

Pleasant Exports distinguishes itself through its specialized focus on finished pharmaceutical formulations, ensuring high-quality products that meet international standards. The company's strategic diversification across therapeutic categories and geographic markets enhances its resilience and growth potential. Additionally, the prequalification of its products by the WHO and possession of EU GMP certificates underscore its commitment to quality and regulatory compliance.

3Strategic Position

Currently, Pleasant Exports maintains a strategic direction centered on the export of generic pharmaceutical formulations, with a focus on high-demand products in oncology and advanced diabetes medications. The company's future outlook includes potential expansion into specialty pharmaceuticals and contract development and manufacturing organization (CDMO) services, leveraging its manufacturing capabilities and regulatory expertise to meet evolving market demands.

Buyer Due Diligence Brief — Evaluating Pleasant Exports as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Pleasant Exports has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $2.9 million USD and 535 shipments across 10 products in 6 therapeutic categories from 2022 to 2026. The company's portfolio concentration, with the top 5 products accounting for 92.6% of exports, indicates a focused approach to high-demand products. The absence of publicly available records of regulatory non-compliance further suggests reliability and adherence to industry standards.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm through the FDA's official website or the company's regulatory filings.

WHO Prequalification: Check the WHO's official prequalification list.

EU GMP Certificate: Obtain from the European Medicines Agency (EMA) or the company's regulatory filings.

Frequently Asked Questions — Pleasant Exports

How many pharmaceutical products does Pleasant Exports export from India?

Pleasant Exports exports 10 pharmaceutical products across 6 therapeutic categories. The top exports are Carboplatin ($1.1M), Semaglutide ($814.8K), Mesalamine ($265.6K), Empagliflozin ($254.7K), Fluticasone ($246.7K). Total export value is $2.9M.

What is Pleasant Exports's total pharmaceutical export value?

Pleasant Exports's total pharmaceutical export value is $2.9M, based on 535 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Pleasant Exports cover?

Pleasant Exports exports across 6 therapeutic categories. The largest are Oncology (37.4%, 1 products), Advanced Diabetes Medications (30.5%, 3 products), Gastrointestinal (9.3%, 1 products).

Get Full Pleasant Exports Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.